HALO

Halozyme monetizes its rHuPH20/ENHANZE subcutaneous drug-delivery platform through royalties and milestones from pharma partners. The economics are excellent: FY2025 revenue grew 37.6% to $1.40B at a 33.6% operating margin and 22.7% net margin, with operating cash flow up 36.0% to $652M on negligible capex of $6.97M. Revenue has compounded steadily from $443M in FY2021, reflecting growing partner-product sales that carry ENHANZE. This is a capital-light, high-return royalty model with structural durability as long as partnered products keep selling and new ENHANZE collaborations are signed.

Two numbers need context. First, net income fell 28.6% to $317M and EPS dropped 25.4% to $2.56 despite the revenue surge — the decline largely reflects rising interest expense as the company took on debt (long-term debt up 42.3% to $2.14B) to fund $342M of buybacks (up 36.9%). Second, the headline 649.2% ROE and 50.73x liabilities/equity are artifacts of an equity base deliberately shrunk to just $48.8M by those buybacks, not signs of distress; the business is strongly cash-generative and capex-light. Still, the debt-funded buyback strategy leaves a thin equity cushion and adds financial risk if royalty cash flows ever wobble.